Biotricity, Inc. (BTCY)
NASDAQ: BTCY · IEX Real-Time Price · USD
0.760
-0.039 (-4.88%)
At close: Jul 2, 2024, 4:00 PM
0.780
+0.020 (2.63%)
After-hours: Jul 2, 2024, 7:39 PM EDT
Company Description
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States.
The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.
It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components.
Biotricity, Inc. is based in Redwood City, California.
Biotricity, Inc.
Country | United States |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 55 |
CEO | Dr. Waqaas Al-Siddiq Ph.D. |
Contact Details
Address: 203 Redwood Parkway, Suite 600 Redwood City, California 94065 United States | |
Phone | (650) 832-1626 |
Website | biotricity.com |
Stock Details
Ticker Symbol | BTCY |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001630113 |
CUSIP Number | 09074H104 |
ISIN Number | US09074H2031 |
Employer ID | 47-2548273 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dr. Waqaas Al-Siddiq Ph.D. | Founder, President, Chief Executive Officer and Chairman |
S. John Ayanoglou | Chief Financial Officer |
Andy Wong | Vice President of Operations |
Dr. George N. Nikopoulos | Director of Business Development |
Matt Zabel | Vice President of Sales and Strategy |
Amir Ali | Chief Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 28, 2024 | DEF 14A | Other definitive proxy statements |
Jun 28, 2024 | 10-K/A | [Amend] Annual report |
Jun 27, 2024 | 10-K | Annual Report |
Jun 24, 2024 | 8-K | Current Report |
Jun 18, 2024 | PRE 14A | Other preliminary proxy statements |
Jun 7, 2024 | 8-K | Current Report |
May 28, 2024 | 8-K | Current Report |
May 28, 2024 | 424B3 | Prospectus |
May 21, 2024 | 8-K | Current Report |
May 16, 2024 | 424B3 | Prospectus |